Literature DB >> 16834751

Tyr2105Cys mutation in exon 22 of FVIII gene is a risk factor for the development of inhibitors in patients with mild/moderate haemophilia A.

M Franchini1, D Girelli, O Olivieri, G Castaman, G Lippi, G Poli, G L Salvagno, G Tagariello, A Giuffrida, M de Gironcoli, M Morfini, E Berntorp, G Gandini.   

Abstract

We report the case of a patient with mild haemophilia A, due to a Tyr2105Cys mutation in exon 22 of the C1 domain, who developed a high-titre factor VIII inhibitor (maximum titre 1600 BU) with recurrent severe haemorrhages and fatal intracranial bleeding. Based on published data, it appears that although this mutation occurs rarely in patients with mild or moderate haemophilia A, it is frequently associated with the development of high-titre inhibitors.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16834751     DOI: 10.1111/j.1365-2516.2006.01297.x

Source DB:  PubMed          Journal:  Haemophilia        ISSN: 1351-8216            Impact factor:   4.287


  4 in total

Review 1.  Inhibitors in mild/moderate haemophilia A: two case reports and a literature review.

Authors:  Anna Chiara Giuffrida; Sabrina Genesini; Massimo Franchini; Marzia De Gironcoli; Giuseppe Aprili; Giorgio Gandini
Journal:  Blood Transfus       Date:  2008-07       Impact factor: 3.443

2.  Eradication of factor VIII inhibitors in patients with mild and moderate hemophilia A.

Authors:  Christine L Kempton; Geoff Allen; Jeffrey Hord; Rebecca Kruse-Jarres; Rajiv K Pruthi; Christopher Walsh; Guy Young; J Michael Soucie
Journal:  Am J Hematol       Date:  2012-06-26       Impact factor: 10.047

Review 3.  Immune response to FVIII in hemophilia A: an overview of risk factors.

Authors:  Kanjaksha Ghosh; Shrimati Shetty
Journal:  Clin Rev Allergy Immunol       Date:  2009-10       Impact factor: 8.667

4.  Acquired haemophilia A as a blood transfusion emergency.

Authors:  Giuseppe Tagariello; Roberto Sartori; Paolo Radossi; Renzo Risato; Giovanni Roveroni; Cristina Tassinari; Annachiara Giuffrida; Giorgio Gandini; Massimo Franchini
Journal:  Blood Transfus       Date:  2008-01       Impact factor: 3.443

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.